CONRAD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, CONRAD sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).

33 total trials none currently recruiting 33 completed early-phase tilt top decile by trial count

CONRAD: 33 sponsored US clinical trials, none currently recruiting.

CONRAD sponsors 33 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 33 completed. 0 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Prevention, with 2 trials.

Top-decile sponsor footprint

CONRAD ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

33 of 33 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

33 total, page 1 of 1

COMPLETED Phase 1

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772

COMPLETED Phase 1

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

NCT03279120

COMPLETED Phase 1

PK and PD Study of Oral F/TAF for HIV Prevention

NCT02904369

COMPLETED Phase 1

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

NCT02722343

COMPLETED Phase 1

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697

COMPLETED NA

Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products

NCT02534779

COMPLETED Phase 1

A Safety Study Of The Caya® Diaphragm Used With ContraGel®

NCT02462954

COMPLETED Phase 1

Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel

NCT02309554

COMPLETED Early Phase 1

Comparison of Tenofovir Vaginal Gel and Film Formulations

NCT02280109

COMPLETED Phase 1

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662

COMPLETED Phase 1

The Role of Vitamin D in Female Reproductive Tract Immunity

NCT02186535

COMPLETED Phase 1

Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

NCT01768962

COMPLETED Phase 1

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

NCT01813162

COMPLETED Phase 1

A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04

NCT01989663

COMPLETED Phase 2

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

NCT01687218

COMPLETED Phase 1

Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity

NCT01810315

COMPLETED

Biomarkers of Protocol Compliance and Product Adherence

NCT01804023

COMPLETED Phase 1

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

NCT01694407

COMPLETED Phase 1

Coital Pharmacokinetics/Pharmacodynamics (PK/PD) of Tenofovir Gel

NCT01687205

COMPLETED Phase 2

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

NCT01593124

COMPLETED Phase 1

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368

COMPLETED Phase 1

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

NCT01369303

COMPLETED NA

Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue

NCT01347632

COMPLETED Phase 1

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

NCT01232803

COMPLETED Phase 1

Microbicide Safety and Acceptability in Young Men

NCT01283360

COMPLETED NA

Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom

NCT01178840

COMPLETED Phase 1

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

NCT00984971

COMPLETED

Residence Time of Biomarkers of Semen Exposure

NCT00984555

COMPLETED Phase 2

Contraceptive Effectiveness and Safety of the SILCS Diaphragm

NCT00578877

COMPLETED Phase 1

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

NCT00561496

COMPLETED Phase 1

Study of UC-781 Vaginal Microbicide

NCT00132444

COMPLETED Phase 2

Contraceptive Effectiveness Trial of Cellulose Sulfate Gel

NCT00255294

COMPLETED Phase 1

Postcoital Testing of the SILCS Diaphragm

NCT00561613

Phase Distribution

PhaseTrial count
Phase 1 24
Phase 2 4

Therapeutic Areas

How the CONRAD early-phase archive is shaped

33 indexed studies, none listed as recruiting (0% open); 33 completed (100%).

Phase mix: 0 late (III/IV) vs 28 early (I/II) (early-phase heavy).

Top condition: HIV Prevention (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

CONRAD: archived-pipeline peers nationwide

Peers matched on 33 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

CONRAD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 010203040 0%5%10%15%20% Total trials Recruiting share CONRADAclaris TherapeuticsAntonios LikourezosBaylor UniversityBecton, Dickinson and Company10xBio22nd Century Group23andMe3-C Institute for Social Development
CONRAD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

CONRAD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 33 archived trials

Sponsors with similar archive density (± trial count)

What to do with this CONRAD page

33 registered trials is a research-attention snapshot, not an endorsement of CONRAD or any single study.

  • None of CONRAD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • HIV Prevention is the condition CONRAD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Prevention trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

CONRAD pipeline card: 33 registered trials from official public datasets.Report a data error.